Jan C. Drooger

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Effects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study.

Effects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study.

Journal: JNCI cancer spectrum

Published: August 29, 2025

Early prediction of menopausal status after chemotherapy in women with early breast cancer in order to optimize adjuvant endocrine therapy.

Early prediction of menopausal status after chemotherapy in women with early breast cancer in order to optimize adjuvant endocrine therapy.

Journal: Breast (Edinburgh, Scotland)

Published: April 14, 2025

Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.

Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.

Journal: Breast cancer research and treatment

Published: September 07, 2023

The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study.

The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study.

Journal: Cancer

Published: August 16, 2023

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival.

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival.

Journal: NPJ breast cancer

Published: February 17, 2023

Development of a Clinical Prediction Model for 1-Year Mortality in Patients With Advanced Cancer.

Development of a Clinical Prediction Model for 1-Year Mortality in Patients With Advanced Cancer.

Journal: JAMA network open

Published: November 30, 2022

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer.

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer.

Journal: ESMO open

Published: October 28, 2022

The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.

The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.

Journal: International journal of cancer

Published: September 16, 2021

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

Journal: Breast cancer research and treatment

Published: September 14, 2020

Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?

Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?

Journal: Breast cancer research and treatment

Published: August 20, 2019

Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies.

Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies.

Journal: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

Published: July 15, 2017

First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.

First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.

Journal: The oncologist

Published: November 11, 2016

Showing 1-12 of 19

Last Updated: 09/26/2026